{"id":"stibophen","rwe":[{"pmid":"8898332","year":"1996","title":"Purification, kinetics and inhibition by antimonials of recombinant phosphofructokinase from Schistosoma mansoni.","finding":"","journal":"Molecular and biochemical parasitology","studyType":"Clinical Study"},{"pmid":"1295239","year":"1992","title":"[Hemolytic anemia caused by excessive use of analgesics].","finding":"","journal":"Wiadomosci lekarskie (Warsaw, Poland : 1960)","studyType":"Clinical Study"},{"pmid":"6090901","year":"1984","title":"Cyclic AMP-dependent and independent protein kinases in Ascaridia galli.","finding":"","journal":"Molecular and biochemical parasitology","studyType":"Clinical Study"},{"pmid":"6264008","year":"1981","title":"Histopathological cochlear changes induced by antimonial antibilharzial drugs.","finding":"","journal":"The Journal of laryngology and otology","studyType":"Clinical Study"},{"pmid":"6248299","year":"1980","title":"Antitrypanosomal activity of trivalent antimonials in vitro and its significance.","finding":"","journal":"Chemotherapy","studyType":"Clinical Study"}],"tags":[{"label":"stibophen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P02BX03","category":"atc"},{"label":"Active","category":"status"},{"label":"Infection by Schistosoma","category":"indication"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"fuadin","offLabel":[],"synonyms":["stibofen","stibophen","fuadin"],"timeline":[],"approvals":[],"brandName":"Fuadin","ecosystem":[{"indication":"Infection by Schistosoma","otherDrugs":[{"name":"oxamniquine","slug":"oxamniquine","company":""},{"name":"praziquantel","slug":"praziquantel","company":"Bayer Hlthcare"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"stibophen","explanation":"Imagine Fuadin as a poison that specifically targets the Schistosoma parasite. When taken, it gets inside the parasite's cells and disrupts their ability to make energy, eventually killing them. This allows the body's immune system to fight off the infection more effectively.","oneSentence":"Fuadin works by interfering with the metabolic processes of Schistosoma parasites, ultimately leading to their death.","technicalDetail":"Fuadin exerts its antiparasitic effects by inhibiting the parasite's glycolytic enzymes, specifically the enzyme phosphoglycerate kinase, which is essential for energy production in the parasite."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4712","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=stibophen","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:41:53.543549","biosimilars":[],"competitors":[{"drugName":"triclabendazole","drugSlug":"triclabendazole","fdaApproval":"2019-02-13","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"stibophen","indications":{"approved":[{"name":"Infection by Schistosoma","source":"DrugCentral","snomedId":10087007,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"triclabendazole","brandName":"triclabendazole","genericName":"triclabendazole","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"002968","UNII":"6CM08O30EH","UMLSCUI":"C0038326","ChEMBL_ID":"CHEMBL1788389","KEGG_DRUG":"D07363","DRUGBANK_ID":"DB13236","PUBCHEM_CID":"16683091","SNOMEDCT_US":"53353009","MESH_SUPPLEMENTAL_RECORD_UI":"C077725"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":41,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"P02BX03","allCodes":["P02BX03"]},"biosimilarFilings":[],"recentPublications":[{"date":"1996 Oct 30","pmid":"8898332","title":"Purification, kinetics and inhibition by antimonials of recombinant phosphofructokinase from Schistosoma mansoni.","journal":"Molecular and biochemical parasitology"},{"date":"1992 Jan","pmid":"1295239","title":"[Hemolytic anemia caused by excessive use of analgesics].","journal":"Wiadomosci lekarskie (Warsaw, Poland : 1960)"},{"date":"1984 Jul","pmid":"6090901","title":"Cyclic AMP-dependent and independent protein kinases in Ascaridia galli.","journal":"Molecular and biochemical parasitology"},{"date":"1981 May","pmid":"6264008","title":"Histopathological cochlear changes induced by antimonial antibilharzial drugs.","journal":"The Journal of laryngology and otology"},{"date":"1980","pmid":"6248299","title":"Antitrypanosomal activity of trivalent antimonials in vitro and its significance.","journal":"Chemotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Fuadin is a trivalent antimony compound used as an anthelmintic, specifically for the treatment of schistosomiasis. It is administered via intramuscular injection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}